BCL2L1 and Thrombocytopenia: PROTAC forms of ABT-263 that degrade BCL-XL and can overcome thrombocytopaenia as E3 ligases are poorly expressed in platelets. Conversion of ABT-263 to PROTACs makes it more specific for BCL-XL.